| 7/21/03 |
Pro-Pharmaceuticals Appoints Noted Carbohydrate Chemist Zbigniew J. Witczak, Ph.D. to Its Scientific Advisory Board |
| 7/15/03 |
Pro-Pharmaceuticals To Host Corporate Presentations in Denver, Austin & Chicago |
| 7/2/03 |
Pro-Pharmaceuticals Announces Publication of Study in Peer-Reviewed Journal Carbohydrate Research |
| 6/24/03 |
Cancer Patients Injected With Pro-Pharmaceuticals? DAVANAT?
in Phase I Clinical Trial at the Norris Cotton Cancer Center
at Dartmouth-Hitchcock Medical |
| 6/20/03 |
Pro-Pharmaceuticals To Host Corporate Presentations |
| 5/29/03 |
Pro-Pharmaceuticals Names Squeglia VP Investor Relations |
| 5/14/03 |
Cancer Patients Injected With Pro-Pharmaceuticals? DAVANAT in Phase I Clinical Trial at the Ochsner Cancer Institute |
| 4/28/03 |
Pro-Pharmaceuticals Receives Patent Allowance for Its Carbohydrate Linker Technology for Anti-Cancer Agents |
| 4/14/03 |
Pro-Pharmaceuticals Appoints Steven Prelack to Board of Directors |
| 4/3/03 |
Pro-Pharmaceuticals Reports Year End Results |
| 3/20/03 |
Pro-Pharmaceuticals Appoints David Christopher as CFO |
| 2/14/03 |
Cancer Patients Injected With Pro-Pharmaceuticals' DAVANAT in Phase I Clinical Trial At Howell, New Jersey Oncology Clinics |
| 2/6/03 |
Pro-Pharmaceuticals Initiates Multi-Center Clinical Trials Of DAVANAT"-1 For All Solid Tumors |
| 1/15/03 |
Pro-Pharmaceuticals Completes Private Placement |
| 1/6/03 |
Pro-Pharmaceuticals Expands Clinical Cancer Trial to Include Additional Solid Tumors |
| 12/30/02 |
Pro-Pharmaceuticals Engages Medidata for Real-Time Electronic Data Collection in its Clinical Cancer Trial |
| 12/19/02 |
Pro-Pharmaceuticals Retains PRA International for Clinical Trial In Cancer Patients |
| 12/10/02 |
Pro-Pharmaceuticals Presents Overview of Carbohydrate Technology To Enhance Existing Cancer Drugs
|
| 11/15/02 |
Pro-Pharmaceuticals Reports Third Quarter Results
|
| 10/22/02 |
Pro-Pharmaceuticals Names Medical Director for Upcoming Clinical Study.
Marilyn Pike engaged as clinical development consultant to oversee firm's Phase I drug trial
|
| 10/7/02 |
Pro-Pharmaceuticals Appoints Mildred Christian to Board of Directors.
Expert on experimental design and government compliance to serve multiple roles with firm |
| 9/25/02 |
Pro-Pharmaceuticals Featured in Genetic Engineering News Overview of
Innovative Cancer Therapy Research |
| 9/12/02 |
Pro-Pharmaceuticals Names University of Michigan Medical School Professor to Scientific Advisory Board. Expert on specialized protein-carbohydrate chemistry to consult on upcoming clinical trials. |
| 9/5/02 |
Pro-Pharmaceuticals Commences Trading on NASD OTC Bulletin Board. Trading Follows FDA Approval of Human Trials With Cancer Drug Enhancement Formulation. |
| 8/26/02 |
Pro-Pharmaceuticals Reports Second Quarter Results |
| 7/29/02 |
Pro-Pharmaceuticals Receives FDA Approval for Phase I Clinical Trial |
| 7/11/02 |
Pro-Pharmaceuticals Announces Public Reporting of Financial Results |
